Director Howard T. Slayen of Aehr Test Systems (NASDAQ:AEHR) disclosed a sale of 25,000 shares of the company common stock on April 17, 2026, at a per-share price of $85.00, for a total reported transaction value of $2,125,000. The transaction was reported in a Form 4 filing with the Securities and Exchange Commission. Following the disposition, the filing shows Slayen still directly holds 178,328 shares, a figure that the company notes includes unvested restricted stock units.
The insider sale takes place with AEHR shares trading near $83.86, after an extraordinary 937% increase over the past 12 months. InvestingPro commentary included in the filing's broader market context flags the stock as appearing overvalued at current levels and lists the company among the platform Most Overvalued stocks. An InvestingPro Tip cited the relative strength index as suggesting overbought conditions and noted that the stock exhibits high price volatility. Investors seeking additional data are pointed to AEHR Pro Research materials, which InvestingPro offers alongside coverage for more than 1,400 other U.S. equities.
Operationally, Aehr Test Systems announced a milestone production order totaling $41 million from a hyperscale customer. The order is for package-level burn-in of custom AI processor ASICs and represents the largest production order in the company's history, according to the announcement. It includes high-power test systems with deliveries scheduled to begin in fiscal 2027.
Financial results for the third quarter of fiscal 2026 showed mixed signals. The company reported a per-share loss of $0.05, which beat the consensus estimate of a $0.07 loss. Revenue, however, fell short of expectations, coming in at $10.3 million versus the $10.8 million analysts had forecast. Despite the revenue miss, Aehr Test Systems recorded a quarterly bookings total of $37.2 million, a company record that the firm and external analysts cited as evidence of strong demand metrics.
Following the operational and results announcements, some analysts adjusted their models. Freedom Broker raised its price target on Aehr Test Systems to $61 from $38 while maintaining a Hold rating. Lake Street also increased its price target, moving it to $56 from $50 and keeping a Buy rating, citing momentum in bookings as the primary rationale.
Taken together, the insider sale, the record production order, the mixed quarterly financials, and the analyst revisions mark a period of heightened activity for Aehr Test Systems. While the company has demonstrated tangible demand in the form of bookings and a notable hyperscale order, valuation commentary from InvestingPro and recent price volatility are points of note for investors monitoring the name.
Methodology note - All transaction and result figures reported here were disclosed in company filings and analyst communications. The Form 4 filing recorded the insider transaction details cited above.